ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 2 مورد

Lidocaine (local and regional anesthetic) and (systemic): Drug information

Lidocaine (local and regional anesthetic) and (systemic): Drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Lidocaine (local and regional anesthetic) and (systemic): Patient drug information" and "Lidocaine (local and regional anesthetic) and (systemic): Pediatric drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: US
  • Lidomark 1/5 [DSC];
  • Lidomark 2/5 [DSC];
  • ReadySharp Lidocaine [DSC];
  • Xylocaine;
  • Xylocaine MPF +RFID;
  • Xylocaine-MPF;
  • Xylocaine-MPF +RFID
Brand Names: Canada
  • Xylocaine;
  • Xylocaine Plain;
  • Xylocard
Pharmacologic Category
  • Antiarrhythmic Agent, Class Ib;
  • Local Anesthetic
Dosing: Adult
Interstitial cystitis

Interstitial cystitis (bladder pain syndrome) (off-label use):

Note: Various dosage regimens of alkalinized lidocaine alone or with heparin (20,000 to 50,000 units) have been used. When lidocaine and heparin are mixed, there is a risk of precipitation if proper alkalinization does not occur. Prior to administration, lidocaine stability and pH should be determined after the components have been mixed (Ref).

Intravesicular: Single instillation: Single bladder installation of lidocaine (200 mg)/heparin (50,000 units)/sodium bicarbonate (420 mg) in 15 mL of sterile water, instilled into the bladder via catheter and allowed to dwell for 30 minutes before drainage (Ref).

Intravesicular: Weekly instillation: Weekly bladder instillations for 12 consecutive weeks with lidocaine 4% (5 mL [200 mg])/heparin (20,000 units)/sodium bicarbonate 7% (25 mL [1,750 mg]), instilled into an empty bladder via catheter and allowed to dwell for 30 minutes before drainage (Ref).

Intravesicular: Daily instillation: Daily bladder instillations for 5 days with lidocaine (200 mg)/sodium bicarbonate 8.4% solution (final volume of 10 mL), instilled into an empty bladder and allowed to dwell for 1 hour before drainage (Ref).

Intraosseous, infusion pain

Intraosseous, infusion pain (off-label use): Note: May consider in a conscious patient to decrease pain prior to the infusion of fluid, medications, or blood products through the intraosseous cannula (Ref).

Lidocaine 2% preservative-free: Intraosseous: Initial dose: 20 or 40 mg over 1 to 2 minutes; may administer 1 or 2 additional doses of 20 mg; follow each dose with an NS flush; maximum total dose not established (Ref).

Local or regional anesthesia

Local or regional anesthesia: Note: Dosage varies with procedure, degree of anesthesia needed, vascularity of tissue, duration of anesthesia required, and physical condition of patient. Calculate weight-based doses using ideal body weight (Ref). General maximum single dose (unless noted otherwise below): 4.5 mg/kg/dose not to exceed 250 to 300 mg; reduced dosages are recommended for patients at high risk for local anesthetic systemic toxicity (Ref). Refer to institutional protocols; doses presented below are examples of recommended volumes and concentrations. Use the lowest concentration and smallest dose to achieve desired result; avoid rapid administration; inject slowly in fractional doses.

Caudal:

Note: The maximum recommended dose should not be administered at intervals of <90 minutes. A 3 mL test dose of lidocaine 1.5% (with epinephrine 1:200,000) given prior to injecting the total volume of lidocaine is recommended for a caudal epidural block. Use of a test dose may serve as a warning of unintentional intravascular or intrathecal injection.

Obstetrical analgesia (preservative free): Lidocaine 1%: 20 to 30 mL; total dose: 200 to 300 mg.

Surgical anesthesia (preservative free): Lidocaine 1.5%: 15 to 20 mL; total dose: 225 to 300 mg.

Epidural:

Note: Dosage varies with the number of dermatomes to be anesthetized (generally 2 to 3 mL of the indicated concentration per dermatome). The maximum recommended dose should not be administered at intervals of <90 minutes. A 3 mL test dose of lidocaine 1.5% (with epinephrine 1:200,000) given prior to injecting the total volume of lidocaine is recommended for a lumbar epidural block. Use of a test dose may serve as a warning of unintentional intravascular or intrathecal injection.

Thoracic epidural anesthesia (preservative free): Lidocaine 1%: 20 to 30 mL; total dose: 200 to 300 mg.

Lumbar epidural anesthesia (preservative free):

Lidocaine 1.5%: 15 to 20 mL; total dose: 225 to 300 mg.

Lidocaine 2%: 10 to 15 mL; total dose: 200 to 300 mg.

Lumbar epidural analgesia (preservative free): Lidocaine 1%: 25 to 30 mL; total dose: 250 to 300 mg.

Infiltration (local anesthesia):

Cutaneous injection (eg, SUBQ or intradermal): Lidocaine 0.5% or 1%: 1 to 60 mL; total dose: 5 to 300 mg.

IV regional anesthesia (eg, Bier block):

Note: Only the single-dose vial containing lidocaine hydrochloride 0.5% injection (without epinephrine) should be used for IV regional anesthesia (Ref).

IV (after tourniquet occlusion of limb to prevent systemic exposure): Lidocaine 0.5%: 10 to 60 mL; total dose: 50 to 300 mg. Usual dosage range: 30 to 50 mL (150 to 250 mg) for upper extremity blocks; maximum dose: 4 mg/kg/dose (Ref).

Nerve block, peripheral (regional anesthesia):

Brachial: Lidocaine 1.5%: 15 to 20 mL; total dose: 225 to 300 mg.

Dental: Lidocaine 2%: 1 to 5 mL; total dose: 20 to 100 mg.

Intercostal: Lidocaine 1%: 3 mL; total dose: 30 mg.

Paravertebral: Lidocaine 1%: 3 to 5 mL; total dose: 30 to 50 mg.

Pudendal (each side): Lidocaine 1%: 10 mL; total dose: 100 mg.

Nerve block, sympathetic (regional anesthesia):

Cervical: Lidocaine 1%: 5 mL; total dose: 50 mg.

Lumbar: Lidocaine 1%: 5 to 10 mL; total dose: 50 to 100 mg.

Paracervical: Obstetrical analgesia (each side): Lidocaine 1%: 10 mL; total dose: 100 mg, wait 5 minutes before administering on other side; maximum dose: 200 mg (100 mg on each side) in a 90 minute period.

Retrobulbar: Lidocaine 4%: 3 to 5 mL; total dose: 120 to 200 mg; a portion of this dose is injected retrobulbarly and the remainder may be used to block the facial nerve.

Ventricular arrhythmias

Ventricular arrhythmias:

Sudden cardiac arrest due to ventricular fibrillation or pulseless ventricular tachycardia (unresponsive to CPR, defibrillation, epinephrine) (off-label use):

Bolus dose:

IV/intraosseous: 1 to 1.5 mg/kg; repeat with 0.5 to 0.75 mg/kg every 5 to 10 minutes as necessary; a typical dose is 50 to 100 mg; maximum cumulative dose: 3 mg/kg or up to 300 mg within 1 hour (Ref).

Endotracheal (off-label route; only use when IV or intraosseous access cannot be established): 2 to 3.75 mg/kg; before administration dilute in 5 to 10 mL NS or sterile water. Note: Absorption is greater with sterile water and results in less impairment of PaO2 (Ref).

Continuous infusion:

Note: Even if lidocaine was not administered during resuscitation but return of spontaneous circulation was achieved, may still consider a lidocaine infusion to prevent recurrent arrhythmia (Ref).

IV/intraosseous : 1 to 4 mg/minute; if used beyond 24 hours, the rate of elimination can be prolonged and dose reduction may be necessary; monitor serum concentrations and signs or symptoms of toxicity to guide dose adjustment; maximum cumulative dose: 300 mg within 1 hour (Ref).

Ventricular tachycardia, hemodynamically stable, sustained monomorphic:

Bolus dose:

IV: 1 to 1.5 mg/kg; repeat with 0.5 to 0.75 mg/kg every 5 to 10 minutes as necessary; a typical dose is 50 to 100 mg; maximum cumulative dose: 3 mg/kg or up to 300 mg within 1 hour (Ref).

Continuous infusion:

Note: Consider for use after bolus dose to prevent recurrent arrhythmia (Ref).

IV: 1 to 4 mg/minute; if used beyond 24 hours, the rate of elimination can be prolonged and dose reduction may be necessary; monitor serum concentrations and signs or symptoms of toxicity to guide dose adjustment; maximum cumulative dose: 300 mg within 1 hour (Ref).

Dosing: Kidney Impairment: Adult

eGFR <30 mL/minute/1.73 m2: Administer lower maintenance infusion rate with close monitoring for toxicity.

Dosing: Liver Impairment: Adult

Administer lower maintenance infusion rate with close monitoring for toxicity.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Lidocaine (local and regional anesthetic) and (systemic): Pediatric drug information")

Ventricular fibrillation or pulseless ventricular tachycardia, shock refractory

Ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT), shock refractory: Infants, Children, and Adolescents:

IV, Intraosseous (Ref): Initial:

Loading dose: 1 mg/kg/dose; follow with continuous IV infusion; may administer second bolus if delay between initial bolus and start of infusion is >15 minutes.

Continuous IV infusion: 20 to 50 mcg/kg/minute. Per manufacturer, do not exceed 20 mcg/kg/minute in patients with shock, hepatic disease, cardiac arrest, or CHF.

Endotracheal: Loading dose: 2 to 3 mg/kg/dose; flush with 5 mL of NS and follow with 5 assisted manual ventilations (Ref).

Anesthesia, local injectable

Anesthesia, local injectable: Dose varies with procedure, degree of anesthesia needed, vascularity of tissue, duration of anesthesia required, and physical condition of patient.

Cutaneous infiltration: Children and Adolescents: Typically solutions with concentration <2% should be used (allow for larger volumes); maximum dose: 5 mg/kg/dose not to exceed the recommended adult maximum dose of 300 mg/dose; do not repeat within 2 hours (Ref).

Intraosseous line or infusion pain: Infants, Children, and Adolescents: Lidocaine 1% or 2 % preservative-free solution: Intraosseous: Initial dose: 0.5 mg/kg over 1 to 2 minutes; usual adult dose range and maximum: 20 to 50 mg/dose; follow with NS flush; immediately following the NS flush, some centers administer a second lower (50% dose reduction) lidocaine dose over 30 to 60 seconds (usual adult maximum repeat dose: 20 mg/dose); if discomfort reoccurs, may repeat doses at a maximum frequency of every 45 minutes during intraosseous access; maximum total dose not established, some centers suggest that dose should not exceed: 3 mg/kg/24 hours (Ref). Note: Intraosseous access devices have a minimum weight and age for a particular device in addition to specific instruction for insertion and validation; consult product specific information for more detail.

Dosing: Kidney Impairment: Pediatric

Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, accumulation of metabolites may be increased in renal dysfunction. Not dialyzable (0% to 5%) by hemo- or peritoneal dialysis; supplemental dose is not necessary (Ref)

Dosing: Liver Impairment: Pediatric

Infants, Children and Adolescents: Use with caution; reduce dose. Monitor lidocaine concentrations closely and adjust infusion rate as necessary; consider alternative therapy. Maximum rate of continuous IV infusion: 20 mcg/kg/minute

Adverse Reactions

The following adverse drug reactions are derived from product labeling unless otherwise specified. Adverse effects may result from high serum concentrations due to rapid absorption, unintentional intravascular administration, unapproved use, or overdose.

Postmarketing:

Cardiovascular: Bradycardia, circulatory shock, hypotension

Gastrointestinal: Vomiting

Hypersensitivity: Hypersensitivity reaction (including nonimmune anaphylaxis)

Nervous system: Abnormal sensory symptoms (including sensation of heat, sensation of cold), apprehension, confusion, dizziness, drowsiness, euphoria, loss of consciousness, nervousness, numbness, seizure, tremor, twitching

Ophthalmic: Blurred vision, diplopia

Otic: Tinnitus

Respiratory: Respiratory depression

Contraindications

Hypersensitivity to lidocaine or any component of the formulation; hypersensitivity to another local anesthetic of the amide type; Adam-Stokes syndrome; Wolff-Parkinson-White syndrome; severe degrees of SA, AV, or intraventricular heart block (except in patients with a functioning artificial pacemaker); premixed injection may contain corn-derived dextrose and its use is contraindicated in patients with allergy to corn or corn-related products.

Canadian labeling: Additional contraindications (not in US labeling): Hypersensitivity to ester local anesthetics (paraben-containing solutions only); supraventricular arrhythmias; severe myocardial depression; antimicrobial preservative-containing solutions should not be used intra-or retro-ocularly or for epidural or spinal anesthesia or any route that would introduce solution into the cerebrospinal fluid or in doses ≥15 mL for other types of blockades.

Warnings/Precautions

Concerns related to adverse effects:

• Intra-articular infusion related chondrolysis: Continuous intra-articular infusion of local anesthetics after arthroscopic or other surgical procedures is not an approved use; chondrolysis (primarily in the shoulder joint) has occurred following infusion, with some cases requiring arthroplasty or shoulder replacement.

• Methemoglobinemia: Has been reported with local anesthetics; clinically significant methemoglobinemia requires immediate treatment along with discontinuation of the anesthetic and other oxidizing agents. Onset may be immediate or delayed (hours) after anesthetic exposure. Patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, exposure to oxidizing agents or their metabolites, or infants <6 months are more susceptible and should be closely monitored for signs and symptoms of methemoglobinemia (eg, cyanosis, headache, rapid pulse, shortness of breath, lightheadedness, fatigue).

Disease-related concerns:

• Hepatic dysfunction: Use extreme caution in patients with severe hepatic dysfunction; may have increased risk of lidocaine toxicity.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer’s labeling.

• Injectable anesthetic: Follow appropriate administration techniques so as not to administer any intravascularly. Solutions containing antimicrobial preservatives should not be used for epidural or spinal anesthesia. Some solutions contain a bisulfite; avoid in patients who are allergic to bisulfite. Resuscitative equipment, medicine and oxygen should be available in case of emergency. Adjust the dose for elderly, pediatric, acutely ill, and debilitated patients.

• Intravenous: Constant ECG monitoring is necessary during IV administration. Use cautiously in hepatic impairment, HF, marked hypoxia, severe respiratory depression, hypovolemia, history of malignant hyperthermia, or shock. Increased ventricular rate may be seen when administered to a patient with atrial fibrillation. Use is contraindicated in patients with Wolff-Parkinson-White syndrome and severe degrees of SA, AV, or intraventricular heart block (except in patients with a functioning artificial pacemaker). Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy. Correct any underlying causes of ventricular arrhythmias. Monitor closely for signs and symptoms of CNS toxicity. The elderly may be prone to increased CNS and cardiovascular side effects. Reduce dose in hepatic dysfunction and CHF.

Other warnings/precautions:

• CAST trial: In the Cardiac Arrhythmia Suppression Trial (CAST), recent (>6 days but <2 years ago) myocardial infarction patients with asymptomatic, non-life-threatening ventricular arrhythmias did not benefit and may have been harmed by attempts to suppress the arrhythmia with flecainide or encainide. An increased mortality or nonfatal cardiac arrest rate (7.7%) was seen in the active treatment group compared with patients in the placebo group (3%). The applicability of the CAST results to other populations is unknown. Antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Kit, Injection, as hydrochloride:

Lidomark 1/5: 1% [DSC]

Lidomark 2/5: 2% [DSC]

ReadySharp Lidocaine: 1% [DSC]

Solution, Injection, as hydrochloride:

Xylocaine: 0.5% (50 mL); 1% (20 mL, 50 mL); 2% (10 mL, 20 mL, 50 mL) [contains methylparaben]

Xylocaine MPF +RFID: 1% (2 mL) [methylparaben free]

Xylocaine-MPF +RFID: 2% (2 mL, 5 mL) [methylparaben free]

Generic: 0.5% (50 mL); 1% (2 mL, 5 mL, 10 mL, 20 mL, 50 mL); 2% (2 mL, 5 mL, 10 mL, 20 mL, 50 mL)

Solution, Injection, as hydrochloride [preservative free]:

Xylocaine-MPF: 0.5% (50 mL); 1% (2 mL, 5 mL, 10 mL, 30 mL); 1.5% (10 mL, 20 mL); 2% (2 mL, 5 mL, 10 mL) [methylparaben free]

Generic: 0.5% (50 mL); 1% (2 mL, 5 mL, 10 mL, 30 mL); 1.5% (20 mL); 2% (2 mL, 5 mL, 10 mL); 4% (5 mL)

Solution, Intravenous, as hydrochloride:

Generic: 0.4% [4 mg/mL] (250 mL, 500 mL); 0.8% [8 mg/mL] (250 mL); 1% [10 mg/mL] (5 mL)

Solution, Intravenous, as hydrochloride [preservative free]:

Generic: 100 mg/5 mL (5 mL)

Solution Prefilled Syringe, Intravenous [preservative free]:

Generic: 100 mg/5 mL (5 mL)

Solution Prefilled Syringe, Injection, as hydrochloride [preservative free]:

Generic: 2% (5 mL)

Solution Prefilled Syringe, Intravenous, as hydrochloride [preservative free]:

Generic: 50 mg/5 mL (5 mL); 100 mg/5 mL (5 mL)

Generic Equivalent Available: US

Yes

Pricing: US

Solution (Lidocaine HCl (Cardiac) PF Intravenous)

100 mg/5 mL (per mL): $0.90

Solution (Lidocaine HCl (PF) Injection)

0.5% (per mL): $0.10

1% (per mL): $0.30 - $19.60

1.5% (per mL): $0.61

2% (per mL): $0.27 - $1.11

4% (per mL): $1.16 - $2.13

Solution (Lidocaine HCl Injection)

0.5% (per mL): $0.11

1% (per mL): $0.10 - $0.37

2% (per mL): $0.09 - $0.19

Solution (Lidocaine in D5W Intravenous)

4 mg/mL 5% (per mL): $0.02

8 mg/mL 5% (per mL): $0.04

Solution (Xylocaine Injection)

0.5% (per mL): $0.13

1% (per mL): $0.10

2% (per mL): $0.23

Solution (Xylocaine MPF +RFID Injection)

1% (per mL): $1.60

Solution (Xylocaine-MPF +RFID Injection)

2% (per mL): $1.94

Solution (Xylocaine-MPF Injection)

0.5% (per mL): $0.35

1% (per mL): $0.38

1.5% (per mL): $0.92

2% (per mL): $0.34

Solution Prefilled Syringe (Lidocaine HCl (Cardiac) Intravenous)

50 mg/5 mL (per mL): $4.75

100 mg/5 mL (per mL): $1.66

Solution Prefilled Syringe (Lidocaine HCl (Cardiac) PF Intravenous)

50 mg/5 mL (per mL): $3.27

100 mg/5 mL (per mL): $1.59

Solution Prefilled Syringe (Lidocaine HCl Injection)

100 mg/5 mL (per mL): $2.15

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Injection, as hydrochloride:

Xylocaine: 0.5% (20 mL)

Xylocaine: 1% (20 mL, 50 mL); 2% (20 mL, 50 mL) [contains methylparaben]

Xylocaine Plain: 1% (2 mL, 5 mL, 10 mL); 2% (2 mL, 5 mL, 10 mL)

Generic: 10 mg/mL (5 mL, 10 mL, 20 mL, 50 mL); 1% (2 mL, 5 mL, 20 mL, 50 mL); 2% (2 mL, 5 mL, 10 mL, 20 mL, 50 mL)

Solution, Intravenous, as hydrochloride:

Xylocard: 2% [20 mg/mL] (5 mL)

Generic: 100 mg/5 mL (5 mL); 0.4% [4 mg/mL] (250 mL, 500 mL); 2% [20 mg/mL] (5 mL)

Solution Prefilled Syringe, Intravenous, as hydrochloride:

Generic: 100 mg/5 mL (5 mL)

Administration: Adult

IV (systemic):

Bolus: According to the manufacturer, may administer at 25 to 50 mg/minute. In the setting of cardiac arrest (eg, ventricular fibrillation or pulseless ventricular tachycardia), may be infused rapidly into a peripheral vein (Ref).

Continuous infusion: After initial bolus dosing, may administer as a continuous infusion; refer to indication-specific infusion rates in dosing for detailed recommendations. In the setting of cardiac arrest, infusion may be initiated once patient has return of spontaneous circulation resulting from lidocaine administration. Local thrombophlebitis may occur in patients receiving prolonged IV infusions.

IV (regional anesthesia): Prior to injection, verify proper tourniquet occlusion of limb to prevent systemic exposure. Administer slowly over ≥90 seconds (Ref).

Cutaneous infiltration (local anesthesia) or perineural infiltration (regional anesthesia): Administer as single or multiple injections, under ultrasound guidance whenever possible; may administer incremental injections or continuously through an indwelling catheter. Avoid rapid injection. Avoid intravascular injections; aspirate syringe prior to each injection; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided (Ref).

The On-Q infusion pump is used to slowly administer local anesthetics (eg, bupivacaine, lidocaine, ropivacaine) to or around surgical wound sites and/or in close proximity to peripheral nerves for postoperative analgesia. When infused directly into the shoulder, destruction of articular cartilage (chondrolysis) has occurred. On-Q pumps should never be placed directly into any joint (Ref).

Endotracheal (off-label administration route): Dilute in NS or sterile water. Absorption is greater with sterile water and results in less impairment of PaO2 (Ref). Stop compressions, spray drug quickly down tube. Flush with 5 mL of NS and follow immediately with several quick insufflations and continue chest compressions.

Epidural and spinal anesthesia: Do not use solutions containing preservatives. Do not puncture areas of the skin with signs of infection. Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided.

Intraosseous (IO; off-label administration route): Intraosseous administration is a reasonable alternative when quick IV access is not feasible (Ref).

Intravesical (off-label use): Various regimens of alkalinized lidocaine (with or without heparin) have been instilled into the bladder (Ref).

Administration: Pediatric

Endotracheal: May administer dose undiluted or may further dilute in 1 to 5 mL NS based on patient size; follow with a flush of ≥5 mL of NS after endotracheal administration; follow with 5 assisted manual ventilations (Ref).

Parenteral:

IV push, Intraosseous:

Ventricular fibrillation or pulseless ventricular tachycardia: The manufacturer recommends that the rate of administration should not exceed 0.7 mg/kg/minute or 50 mg/minute, whichever is less; however, during acute situations, administration by rapid IV push has been used by some clinicians in practice.

Neonatal seizures: Loading doses are usually administered over 10 minutes (Ref).

Continuous IV infusion: Administer via an infusion pump.

SUBQ/local infiltration: May use plain or buffered lidocaine; for circumcisions, use a 23- to 27-gauge needle for administration (Ref).

Usual Infusion Concentrations: Adult

Note: Premixed solutions available.

IV infusion: 1,000 mg in 250 mL (concentration: 4 mg/mL) or 2,000 mg in 250 mL (concentration: 8 mg/mL) of D5W.

Usual Infusion Concentrations: Pediatric

Note: Premixed solutions available.

IV infusion: 4 mg/mL, 8 mg/mL.

Use: Labeled Indications

Local or regional anesthesia: Local and regional anesthesia by infiltration, nerve block, epidural, or spinal techniques.

Ventricular tachycardia, hemodynamically stable, sustained monomorphic: Acute treatment of ventricular arrhythmias (eg, due to acute myocardial infarction [MI] or during cardiac manipulation [eg, cardiac surgery]).

Note: The routine prophylactic use of lidocaine to prevent arrhythmia associated during ST-elevation MI or to suppress isolated ventricular premature beats, couplets, runs of accelerated idioventricular rhythm, and nonsustained ventricular tachycardia is not recommended (ACCF/AHA [O'Gara 2013]).

Use: Off-Label: Adult

Interstitial cystitis (bladder pain syndrome); Intraosseous, infusion pain; Sudden cardiac arrest due to ventricular fibrillation or pulseless ventricular tachycardia (unresponsive to CPR, defibrillation, and epinephrine)

Medication Safety Issues
High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes (antiarrhythmic agent, IV; epidural and intrathecal medications) which have a heightened risk of causing significant patient harm when used in error (High-Alert Medications in Acute Care Settings).

International issues:

Lidosen [Italy] may be confused with Lincocin brand name for lincomycin [US, Canada, and multiple international markets]; Lodosyn brand name for carbidopa [US].

Metabolism/Transport Effects

Substrate of CYP1A2 (Major), CYP2A6 (Minor), CYP2B6 (Minor), CYP2C9 (Minor), CYP3A4 (Major with inhibitors), CYP3A4 (Minor with inducers); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Amiodarone: May increase serum concentration of Lidocaine (Systemic). Risk C: Monitor

Articaine: May increase adverse/toxic effects of Local Anesthetics. Risk C: Monitor

Broccoli: May decrease serum concentration of CYP1A2 Substrates (High risk with Inducers). Risk C: Monitor

BUPivacaine (Liposomal): Lidocaine (Systemic) may increase adverse/toxic effects of BUPivacaine (Liposomal). Management: Liposomal bupivacaine should not be administered with lidocaine. Liposomal bupivacaine may be administered 20 minutes or more after the administration of lidocaine. Lidocaine may be administered 96 hours or more after liposomal bupivacaine administration. Risk D: Consider Therapy Modification

BUPivacaine: Local Anesthetics may increase adverse/toxic effects of BUPivacaine. Management: Avoid using any additional local anesthetics within 96 hours after insertion of the bupivacaine implant (Xaracoll) or bupivacaine and meloxicam periarticular solution (Zynrelef) or within 168 hours after subacromial infiltration (Posimir brand). Risk C: Monitor

Cannabis: May decrease serum concentration of CYP1A2 Substrates (High risk with Inducers). Risk C: Monitor

Cimetidine: May increase serum concentration of Lidocaine (Systemic). Risk C: Monitor

Clofazimine: May increase serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor

CYP1A2 Inducers (Moderate): May decrease serum concentration of Lidocaine (Systemic). Risk C: Monitor

CYP1A2 Inhibitors (Strong): May increase serum concentration of Lidocaine (Systemic). Risk C: Monitor

CYP3A4 Inducers (Strong): May decrease serum concentration of Lidocaine (Systemic). Risk C: Monitor

CYP3A4 Inhibitors (Moderate): May increase serum concentration of Lidocaine (Systemic). CYP3A4 Inhibitors (Moderate) may increase active metabolite exposure of Lidocaine (Systemic). Specifically, concentrations of monoethylglycinexylidide (MEGX) may be increased. Risk C: Monitor

CYP3A4 Inhibitors (Strong): May increase serum concentration of Lidocaine (Systemic). Risk C: Monitor

Dapsone (Topical): May increase adverse/toxic effects of Methemoglobinemia Associated Agents. Risk C: Monitor

Diazoxide Choline: May increase serum concentration of CYP1A2 Substrates (High risk with Inhibitors). Risk X: Avoid

Disopyramide: May increase arrhythmogenic effects of Lidocaine (Systemic). Disopyramide may increase serum concentration of Lidocaine (Systemic). Specifically, the unbound/free fraction of lidocaine may be increased. Risk C: Monitor

Etravirine: May decrease serum concentration of Lidocaine (Systemic). Risk C: Monitor

Fusidic Acid (Systemic): May increase serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Consider avoiding this combination if possible. If required, monitor patients closely for increased adverse effects of the CYP3A4 substrate. Risk D: Consider Therapy Modification

Grapefruit Juice: May increase serum concentration of Lidocaine (Systemic). Grapefruit Juice may increase active metabolite exposure of Lidocaine (Systemic). Specifically, concentrations of monoethylglycinexylidide (MEGX) may be increased. Risk C: Monitor

Hyaluronidase: May increase adverse/toxic effects of Local Anesthetics. Risk C: Monitor

Lacosamide: Lidocaine (Systemic) may increase adverse/toxic effects of Lacosamide. Specifically the risk for bradycardia, ventricular tachyarrhythmias, or a prolonged PR interval may be increased. Risk C: Monitor

Lidocaine (Topical): May increase adverse/toxic effects of Antiarrhythmic Agents (Class IB). Risk C: Monitor

Local Anesthetics: Methemoglobinemia Associated Agents may increase adverse/toxic effects of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. Risk C: Monitor

Methemoglobinemia Associated Agents: May increase adverse/toxic effects of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. Risk C: Monitor

Neuromuscular-Blocking Agents: Local Anesthetics may increase neuromuscular-blocking effects of Neuromuscular-Blocking Agents. Risk C: Monitor

Nitric Oxide: May increase adverse/toxic effects of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Risk C: Monitor

Phenobarbital-Primidone: May decrease serum concentration of Lidocaine (Systemic). Risk C: Monitor

Prilocaine: Methemoglobinemia Associated Agents may increase adverse/toxic effects of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor for signs of methemoglobinemia when prilocaine is used in combination with other agents associated with development of methemoglobinemia. Avoid use of these agents with prilocaine/lidocaine cream in infants less than 12 months of age. Risk C: Monitor

Primaquine: Methemoglobinemia Associated Agents may increase adverse/toxic effects of Primaquine. Specifically, the risk for methemoglobinemia may be increased. Management: Avoid concomitant use of primaquine and other drugs that are associated with methemoglobinemia when possible. If combined, monitor methemoglobin levels closely. Risk D: Consider Therapy Modification

Propranolol: May increase serum concentration of Lidocaine (Systemic). Risk C: Monitor

ROPivacaine: May increase adverse/toxic effects of Local Anesthetics. Risk C: Monitor

Saquinavir: May increase serum concentration of Lidocaine (Systemic). Risk X: Avoid

Sodium Nitrite: Methemoglobinemia Associated Agents may increase adverse/toxic effects of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Risk C: Monitor

Technetium Tc 99m Tilmanocept: Coadministration of Local Anesthetics and Technetium Tc 99m Tilmanocept may alter diagnostic results. Management: Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anesthetics. This interaction does not appear to apply to other uses of these agents in combination. Risk C: Monitor

Tobacco (Smoked): May decrease serum concentration of Lidocaine (Systemic). Risk C: Monitor

Pregnancy Considerations

Lidocaine and its metabolites cross the placenta and can be detected in the fetal circulation following maternal injection for anesthesia prior to delivery (Cavalli 2004; Mitani 1987).

Adverse reactions in the fetus/neonate may affect the CNS, heart, or peripheral vascular tone. Fetal heart monitoring is recommended by the manufacturer.

Lidocaine injection is approved for obstetric analgesia (eg, prior to epidural or spinal anesthesia). Lidocaine administered by local infiltration is used to provide analgesia prior to episiotomy and during repair of obstetric lacerations (ACOG 209 2019). Administration by the perineal route may result in greater absorption than administration by the epidural route (Cavalli 2004). Cumulative exposure from all routes of administration should be considered. The ACOG recommends that pregnant patients should not be denied medically necessary surgery regardless of trimester. If the procedure is elective, it should be delayed until after delivery (ACOG 775 2019).

Medications used for the treatment of cardiac arrest in pregnancy are the same as in the nonpregnant woman. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines. Appropriate medications should not be withheld due to concerns of fetal teratogenicity (AHA [Jeejeebhoy 2015]).

Breastfeeding Considerations

Lidocaine is present in breast milk.

• Data related to the presence of lidocaine in breast milk are available following maternal administration of lidocaine via local regional anesthesia to 22 patients undergoing cesarean delivery. Patients received a mean dose of lidocaine 183 ± 104 mg. Lidocaine concentrations 2 hours after the injection were 0.86 ± 0.79 mcg/mL (breast milk) and 0.94 ± 0.54 mcg/mL (maternal serum). Breast milk concentrations of lidocaine decreased over 12 hours. Adverse events were not observed in the breastfed infants (Ortega 1999).

• Lidocaine concentrations in breast milk have been evaluated in lactating patients following use as a dental anesthetic (Giuliani 2001; Lebedevs 1993; Puente 2001). In one study, patients were administered lidocaine 2% (3.6 mL) (n=6), lidocaine 2% (4.5 mL) (n=1), or lidocaine 2% (7.2 mL) (n=1). Breast milk was sampled 3 and 6 hours after the dose; maternal serum was sampled 2 hours after the dose. Lidocaine concentrations were 0.078 to 0.25 mcg/mL (breast milk at 3 hours), 0.0283 to 0.107 mcg/mL (breast milk at 6 hours), and 0.196 to 0.869 mcg/mL (maternal serum at 2 hours). The active metabolite monoethylglycinexylidide (MEGX) was also present in breast milk and maternal serum at all sampling times. Breast milk concentrations of MEGX were greatest 3 hours after the maternal dose (0.0333 to 0.143 mcg/mL). Infants were not breastfed in this study (Giuliani 2001).

• Lidocaine was detected in breast milk following use in a tumescent liposuction procedure. The patient received a total of 4,200 mg throughout the procedure. Lidocaine concentrations were 0.55 mcg/mL (breast milk) and 1.2 mcg/mL (maternal serum) at the expected peak plasma time, 18 hours after the surgery. The infant was not breastfed (Dryden 2000).

• Breast milk was sampled in a patient following a lidocaine infusion for treatment of a maternal arrythmia. The 86 kg lactating patient who had a history of mitral valve prolapse presented to the emergency room with heart palpitations and chest pain. A lidocaine 75 mg IV bolus was administered, followed by a second lidocaine 50 mg IV bolus after 5 minutes. A lidocaine 23 mcg/kg/minute infusion was started with the first bolus. Five hours after lidocaine was initiated, maternal serum concentrations were 2 mcg/mL; the infusion was then discontinued 2 hours later. Lidocaine breast milk concentrations after the infusion was stopped were 0.8 mcg/mL (Zeisler 1986).

• Oral bioavailability of lidocaine to the breastfeeding infant is expected to be low (Lebedevs 1993; Ortega 1999).

Available guidelines consider lidocaine to be compatible with breastfeeding when used as an antiarrhythmic or local anesthetic (ABM [Reece-Stremtan 2017]; WHO 2002). Cumulative exposure from all routes of administration should be considered.

Dietary Considerations

Premixed injection may contain corn-derived dextrose and its use is contraindicated in patients with allergy to corn-related products.

Monitoring Parameters

LFTs, ECG; neurologic signs and symptoms of toxicity (eg, perioral tingling, tinnitus, light-headedness, restlessness); in patients requiring continuous infusions or therapy >24 hours, lidocaine serum concentrations if available and clinically relevant; consult individual institutional policies and procedures.

Reference Range

Note: These ranges act as a general guide only; the correlation between toxic symptoms and plasma lidocaine concentrations is not fully reliable. Vulnerable patients may experience toxicity at lower levels (Foo 2021; Samarin 2015).

Therapeutic: 1.5 to 5 mcg/mL (SI: 6.4 to 21.3 micromole/L).

Toxicity more common: >6 mcg/mL (SI: >25.6 micromole/L).

Mechanism of Action

Class Ib antiarrhythmic; suppresses automaticity of conduction tissue, by increasing electrical stimulation threshold of ventricle, His-Purkinje system, and spontaneous depolarization of the ventricles during diastole by a direct action on the tissues; blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Systemic administration: Single IV bolus dose: 45 to 90 seconds.

Duration: Systemic administration: Single IV bolus dose: 10 to 20 minutes.

Distribution: Systemic administration: Single IV bolus dose: 0.8 to 2.8 L/kg (Berkenstadt 1999); alterable by many patient factors; decreased in heart failure and liver disease; crosses blood-brain barrier.

Protein binding: Dependent on drug concentration; fraction bound decreases with increasing concentration. At 1 to 4 mcg/mL, 60% to 80% bound to alpha1 acid glycoprotein.

Metabolism: 90% hepatic via CYP1A2 and CYP3A4; active metabolites monoethylglycinexylidide (MEGX) and glycinexylidide (GX) can accumulate and may cause CNS toxicity.

Half-life elimination: Systemic administration: Biphasic: Initial: ~8 minutes following single IV bolus (Burm 1988); Terminal: Infants, premature: 3.2 hours; Adults: 1.5 to 2 hours following single IV bolus (Burm 1988; manufacturer's labeling). Prolonged with continuous infusions >24 hours, heart failure, liver disease, shock, severe renal impairment, neonatal therapeutic hypothermia (van den Broek 2013; manufacturer's labeling).

Excretion: Urine (<10% as unchanged drug, ~90% as metabolites).

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Xylocaine | Xylocard;
  • (AT) Austria: Xylocard;
  • (AU) Australia: Lignocaine | Xylocaine | Xylocard;
  • (BD) Bangladesh: Lidocaine;
  • (BE) Belgium: Lidocaine accord;
  • (BG) Bulgaria: Lidocain;
  • (BR) Brazil: Xylocaina;
  • (CN) China: Li shu ka | Lidocaine | Lidocaine aerosol (ii);
  • (CO) Colombia: Farmacaina | Lidocaina | Roxicaina | Xylocaina;
  • (DE) Germany: Lidocain Braun | Lidocain hcl B. Braun | Lidocard | Min-I-Jet Lidocain | Ryligency | Xylocain | Xylonor n;
  • (EC) Ecuador: Roxicaina;
  • (EE) Estonia: Xylocaine;
  • (EG) Egypt: Lidocaine;
  • (ES) Spain: Xilonibsa;
  • (FI) Finland: Lidocard | Xylocain | Xylocard;
  • (FR) France: Ryligency | Xylocard;
  • (GB) United Kingdom: Lignocaine | Sure | Xylocard;
  • (HK) Hong Kong: Xylocaine | Xylocard;
  • (HU) Hungary: Lidocain;
  • (IE) Ireland: Xylocard;
  • (IL) Israel: Stud 100;
  • (IT) Italy: Lidocaina abbott;
  • (JO) Jordan: Avocaine;
  • (JP) Japan: Lidocaine | Olives | Olives k | Olives takata | Xylocaine;
  • (KR) Korea, Republic of: Xylocaine;
  • (KW) Kuwait: Lidocaine HCL | Ryligency | Xylocard | Xylonor;
  • (LB) Lebanon: Lidocaine | Procomil | Xylocaine;
  • (LV) Latvia: Xylocard;
  • (MX) Mexico: Mortelec;
  • (MY) Malaysia: Xylocard;
  • (NL) Netherlands: Xylocaine | Xylocard;
  • (NO) Norway: Lidokain sad | Lignocaine hydrochloride fresenius | Xylocard;
  • (NZ) New Zealand: Xylocaine plain | Xylocard;
  • (PE) Peru: Lidocaina | Roxicaina | Xilonest s.p. | Xylocaina;
  • (PH) Philippines: Xylocaine;
  • (PK) Pakistan: Lignocaine;
  • (PL) Poland: Lidocain | Lignocainum | Xylocain;
  • (PR) Puerto Rico: Aspercreme with lidocaine | Lidocaine HCL | Xylocaine cardiac;
  • (PT) Portugal: Lidocaina | Lidocaina braun | Lidoject | Xylocard;
  • (PY) Paraguay: Lidocaina veinfar;
  • (QA) Qatar: Lignoc | Medocaine | Zylodine;
  • (RU) Russian Federation: Lidocain;
  • (SA) Saudi Arabia: Xylocaine | Xylocard;
  • (SE) Sweden: Xylocain | Xylocard;
  • (SG) Singapore: Xylocard;
  • (SI) Slovenia: Xylocain;
  • (SR) Suriname: Lidocaine hcl cf;
  • (TH) Thailand: Xylocaine | Xylocard;
  • (TW) Taiwan: Lidocain | Lidocaine | Lignocaine | Xylocaine;
  • (UA) Ukraine: Lidocain;
  • (UY) Uruguay: Xylo Efa Cardiolog;
  • (VE) Venezuela, Bolivarian Republic of: Farmacaina
  1. Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
  2. Al Baqui SA, Khan TH, Mollah AH, et al. Comparative efficacy of phenytoin versus lidocaine in the management of intractable seizure in neonate. J Dhaka Med Coll. 2016;25(2):94-99. doi:10.3329/jdmc.v25l2.33973
  3. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death [published correction appears in Circulation. 2018;138(13):e419-e420]. Circulation. 2018;138(13):e272-e391. doi: 10.1161/CIR.0000000000000549. [PubMed 29084731]
  4. American Academy of Pediatrics (AAP) Task Force on Circumcision. Male circumcision. Pediatrics. 2012;130(3):e756-e785. doi:10.1542/peds.2012-1990 [PubMed 22926175]
  5. American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 209: obstetric analgesia and anesthesia. Obstet Gynecol. 2019;133(3):e208-e225. [PubMed 30801474]
  6. American College of Obstetricians and Gynecologists (ACOG). ACOG committee opinion no. 775: nonobstetric surgery during pregnancy. Obstet Gynecol. 2019;133(4):e285-e286. [PubMed 30913200]
  7. American Society of Health-System Pharmacists (ASHP). Adult continuous infusion standards. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Adult-Infusion-Standards.pdf. Published October 2023b. Accessed December 11, 2023.
  8. American Society of Health-System Pharmacists (ASHP). Pediatric continuous infusion standards. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Pediatric-Infusion-Standards.ashx. Updated March 2024. Accessed April 10, 2024.
  9. Anand KJ; International Evidence-Based Group for Neonatal Pain. Consensus statement for the prevention and management of pain in the newborn. Arch Pediatr Adolesc Med. 2001;155(2):173-180. doi:10.1001/archpedi.155.2.173 [PubMed 11177093]
  10. Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of Physicians; 2007.
  11. Berkenstadt H, Segal E, Mayan H, et al. The pharmacokinetics of morphine and lidocaine in critically ill patients. Intensive Care Med. 1999;25(1):110-112. doi:10.1007/s001340050796 [PubMed 10051088]
  12. Bohnhorst B, Hartmann H, Lange M. Severe methemoglobinemia caused by continuous lidocaine infusion in a term neonate. Eur J Paediatr Neurol. 2017;21(3):576-579. doi:10.1016/j.ejpn.2016.12.011 [PubMed 28082013]
  13. Burm AG, de Boer AG, van Kleef JW, et al. Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. Biopharm Drug Dispos. 1988;9(1):85-95. doi:10.1002/bod.2510090109 [PubMed 3342287]
  14. Cavalli Rde C, Lanchote VL, Duarte G, et al, "Pharmacokinetics and Transplacental Transfer of Lidocaine and its Metabolite For Perineal Analgesic Assistance to Pregnant Women," Eur J Clin Pharmacol, 2004, 60(8):569-74. [PubMed 15365654]
  15. Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
  16. Christoph RA, Buchanan L, Begalla K, Schwartz S. Pain reduction in local anesthetic administration through pH buffering. Ann Emerg Med. 1988;17(2):117-120. [PubMed 2827545]
  17. de Caen AR, Berg MD, Chameides L, et al. Part 12: Pediatric Advanced Life Support: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132(18 Suppl 2):S526-S542. [PubMed 26473000]
  18. de Oliveira Duque-Estrada E. The use of buffering solutions in the pediatrics local anesthesia to reduce the pain of minor procedures. Biomed J Sci & Tech Res. 2018;2(1):2363-2364. doi:10.26717/BISTR.2018.02.000695
  19. Dorian P, Cass D, Schwartz B, et al. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med. 2002; 346:884-890. [PubMed 11907287]
  20. Dryden RM, Lo MW. Breast milk lidocaine levels in tumescent liposuction. Plast Reconstr Surg. 2000;105(6):2267-2268. doi:10.1097/00006534-200005000-00063 [PubMed 10839430]
  21. Duff JP, Topjian A, Berg MD, et al. 2018 American Heart Association focused update on pediatric advanced life support: an update to the American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2018;138(23):e731-e739. [PubMed 30571264]
  22. Favié LMA, Huitema ADR, van den Broek MPH, et al. Lidocaine as treatment for neonatal seizures: evaluation of previously developed population pharmacokinetic models and dosing regimen. Br J Clin Pharmacol. 2020;86(1):75-84. doi:10.1111/bcp.14136 [PubMed 31663153]
  23. Field JM, Hazinski MF, Sayre MR, et al, "Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care," Circulation, 2010, 122(18 Suppl 3):640-56. [PubMed 20956217]
  24. Foo I, Macfarlane AJR, Srivastava D, et al. The use of intravenous lidocaine for postoperative pain and recovery: international consensus statement on efficacy and safety. Anaesthesia. 2021;76(2):238-250. doi:10.1111/anae.15270 [PubMed 33141959]
  25. Giuliani M, Grossi GB, Pileri M, Lajolo C, Casparrini G. Could local anesthesia while breast-feeding be harmful to infants? J Pediatr Gastroenterol Nutr. 2001;32(2):142-144. doi:10.1097/00005176-200102000-00009 [PubMed 11321382]
  26. Goyal NK. Circumcision. In: Kliegman RM, St. Geme J, eds. Nelson Textbook of Pediatrics. 21st ed. Elsevier; 2020:chap. 113.4.
  27. Hähnel JH, Lindner KH, Schürmann C, et al, "Plasma Lidocaine Levels and PaO2 With Endobronchial Administration: Dilution With Normal Saline or Distilled Water?" Ann Emerg Med, 1990, 19(11):1314-7. [PubMed 2240730]
  28. Hanno PM, Burks DA, Clemens JQ, et al; American Urological Association Education and Research Inc. American Urological Association guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. Published 2011. Updated December 5, 2014. Accessed March 17, 2020. https://www.auanet.org/guidelines/interstitial-cystitis-(ic/bps)-guideline
  29. Hanno PM, Burks DA, Clemens Q, et al; American Urological Association. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome. https://www.auanet.org/guidelines-and-quality/guidelines/diagnosis-and-treatment-interstitial-of-cystitis/bladder-pain-syndrome-(2022). Published 2011. Updated 2022. Accessed August 24, 2023.
  30. Hazinski MF, Samson R, Schexnayder S. 2010 Handbook of Emergency Cardiovascular Care for Healthcare Providers. South Deerfield, MA: American Heart Association; 2010.
  31. Hegenbarth MA, American Academy of Pediatrics Committee on Drugs. Preparing for pediatric emergencies: drugs to consider. Pediatrics. 2008;121(2):433-443. [PubMed 18245435]
  32. Hartholt KA, van Lieshout EM, Thies WC, Patka P, Schipper IB. Intraosseous devices: a randomized controlled trial comparing three intraosseous devices. Prehosp Emerg Care. 2010;14(1):6-13. doi: 10.3109/10903120903349861. [PubMed 19947861]
  33. Hockett D, Kress L, Mac Donald R, Krenzischek DA, Maheshwari A. Effectiveness of buffered lidocaine for local anesthesia during liver biopsy. Gastroenterol Nurs. 2021;44(3):172-176. doi:10.1097/SGA.0000000000000542 [PubMed 33927155]
  34. Holliday MA, Pinckert TL, Kiernan SC, Kunos I, Angelus P, Keszler M. Dorsal penile nerve block vs topical placebo for circumcision in low-birth-weight neonates. Arch Pediatr Adolesc Med. 1999;153(5):476-480. doi:10.1001/archpedi.153.5.476 [PubMed 10323627]
  35. Hyland SJ, Wolfe RC, Patel G, Johnson EG. Perioperative medical emergencies: the role of clinical pharmacists and a review of pharmacotherapy considerations. J Am Coll Clin Pharm. 2023;6:1053-1070. doi:10.1002/jac5.1762
  36. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  37. Institute for Safe Medication Practice (ISMP). Process for handling elastomeric pain relief balls (ON-Q PainBuster and others) requires safety improvements. ISMP Medication Safety Alert. Published July 16, 2009a. Accessed December 12, 2023.
  38. Institute for Safe Medication Practice (ISMP). Survey on LASA drug name pairs: who knows what’s on your list and the best ways to prevent mix-ups? ISMP Medication Safety Alert. Published May 21, 2009b. Accessed December 12, 2023.
  39. Jeejeebhoy FM, Zelop CM, Lipman S, et al; American Heart Association Emergency Cardiovascular Care Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Diseases in the Young, and Council on Clinical Cardiology. Cardiac Arrest in Pregnancy: A Scientific Statement From the American Heart Association. Circulation. 2015;132(18):1747-1773. [PubMed 26443610]
  40. Klaus JR, Knodel LC, Kavanagh RE. Administration guidelines for parenteral drug therapy. Part I: pediatric patients. J Pharm Technol. 1989;5(3):101-128. [PubMed 10318297]
  41. Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: Pediatric advanced life support: 2010 American Heart Association Guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation, 2010;122(18 Suppl 3):S876-S908. [PubMed 20956230]
  42. Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. Nelson' s Textbook of Pediatrics. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.
  43. Lander J, Brady-Fryer B, Metcalfe JB, Nazarali S, Muttitt S. Comparison of ring block, dorsal penile nerve block, and topical anesthesia for neonatal circumcision: a randomized controlled trial. JAMA. 1997;278(24):2157-2162. [PubMed 9417009]
  44. Lebedevs TH, Wojnar-Horton RE, Yapp P, et al. Excretion of lignocaine and its metabolite monoethylglycinexylidide in breast milk following its use in a dental procedure. A case report. J Clin Periodontol. 1993;20(8):606-608. doi:10.1111/j.1600-051x.1993.tb00779.x [PubMed 8408724]
  45. Lidocaine 1% and 2% (Ansyr, Lifeshield Abboject) syringes (lidocaine) injection, USP [prescribing information]. Lake Forest, IL: Hospira Inc; April 2018.
  46. Lidocaine hydrochloride injection 4% ampules [prescribing information]. Lake Forest, IL: Hospira; July 2021.
  47. Löser B, Petzoldt M, Löser A, Bacon DR, Goerig M. Intravenous regional anesthesia: a historical overview and clinical review. J Anesth Hist. 2019;5(3):99-108. doi:10.1016/j.janh.2018.10.007 [PubMed 31570204]
  48. Malingré MM, Van Rooij LG, Rademaker CM, et al. Development of an optimal lidocaine infusion strategy for neonatal seizures. Eur J Pediatr. 2006;165(9):598-604. [PubMed 16691409]
  49. Maxwell LG, Yaster M, Wetzel RC, Niebyl JR. Penile nerve block for newborn circumcision. Obstet Gynecol. 1987;70(3 Pt 1):415-419. [PubMed 3627593]
  50. Mitani GM, Steinberg I, Lien EJ, et al, "The Pharmacokinetics of Antiarrhythmic Agents in Pregnancy and Lactation," Clin Pharmacokinet, 1987, 12(4):253-91. [PubMed 3297463]
  51. Moore PA and Hersh EV, "Local Anesthetics: Pharmacology and Toxicity," Dent Clin North Am, 2010, 54(4):587-99. [PubMed 20831923]
  52. Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations. Am J Health Syst Pharm. 2014;71(17):1500-1508. [PubMed 25147175]
  53. Nagler J, Krauss B. Videos in clinical medicine. Intraosseous catheter placement in children. N Engl J Med. 2011;364(8):e14. doi: 10.1056/NEJMvcm0900916. [PubMed 21345096]
  54. Neal JM, Woodward CM, Harrison TK. The American Society of Regional Anesthesia and Pain Medicine checklist for managing local anesthetic systemic toxicity: 2017 version. Reg Anesth Pain Med. 2018;43(2):150-153. doi:10.1097/AAP.0000000000000726 [PubMed 29356775]
  55. Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010;122(18 Suppl 3):729-767. [PubMed 20956224]
  56. Nickel JC, Moldwin R, Lee S, Davis EL, Henry RA, Wyllie MG. Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome. BJU Int. 2009;103(7):910-918. [PubMed 19021619]
  57. Nomiya A, Naruse T, Niimi A, et al. On- and post-treatment symptom relief by repeated instillations of heparin and alkalized lidocaine in interstitial cystitis. Int J Urol. 2013;20(11):1118-1122. [PubMed 23432185]
  58. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in Circulation. 2013;128(25):e481.] Circulation. 2013;127(4):e362-e425. [PubMed 23247304]
  59. Ogundele IO, Nwokoro CC, Adedeji TA, et al. Comparison of dorsal penile nerve block alone and in combination with lidocaine-prilocaine cream in neonates undergoing circumcision: a randomized controlled study. World J Pediatr Surg. 2022;5(4):e000470. doi:10.1136/wjps-2022-000470 [PubMed 36474739]
  60. Omole F, Smith W, Carter-Wicker K. Newborn circumcision techniques. Am Fam Physician. 2020;101(11):680-685. [PubMed 32463643]
  61. Ortega D, Viviand X, Lorec AM, Gamerre M, Martin C, Bruguerolle B. Excretion of lidocaine and bupivacaine in breast milk following epidural anesthesia for cesarean delivery. Acta Anaesthesiol Scand. 1999;43(4):394-397. doi:10.1034/j.1399-6576.1999.430405.x [PubMed 10225071]
  62. Panchal AR, Bartos JA, Cabañas JG, et al; Adult Basic and Advanced Life Support Writing Group. Part 3: adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2020;142(16 suppl 2):S366-S468. doi:10.1161/CIR.0000000000000916 [PubMed 33081529]
  63. Parsons CL, Zupkas P, Proctor J, et al. Alkalinized lidocaine and heparin provide immediate relief of pain and urgency in patients with interstitial cystitis. J Sex Med. 2012;9(1):207-212. [PubMed 22082303]
  64. Pascuet E, Donnelly RF, Garceau D, Vaillancourt R. Buffered lidocaine hydrochloride solution with and without epinephrine: stability in polypropylene syringes. Can J Hosp Pharm. 2009;62(5):375-380. doi:10.4212/cjhp.v62i5.824 [PubMed 22478919]
  65. Peberdy MA, Callaway CW, Neumar RW, et al. Part 9: Post Cardiac Arrest Care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(18) (suppl 3):768-786. [PubMed 20124120]
  66. Perman SM, Elmer J, Maciel CB, et al; American Heart Association. 2023 American Heart Association focused update on adult advanced cardiovascular life support: an update to the American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2024;149(5):e254-e273. doi:10.1161/CIR.0000000000001194 [PubMed 38108133]
  67. Philbeck TE, Miller LJ, Montez D, Puga T. Hurts so good. Easing IO pain and pressure. JEMS. 2010;35(9):58-62, 65-6, 68; quiz 69. doi:10.1016/S0197-2510(10)70232-1. [PubMed 20868946]
  68. Phillips MS, "Standardizing I.V. Infusion Concentrations: National Survey Results," Am J Health Syst Pharm, 2011, 68(22):2176-82. [PubMed 22058104]
  69. Pressler RM, Abend NS, Auvin S, et al. Treatment of seizures in the neonate: guidelines and consensus-based recommendations-special report from the ILAE Task Force on Neonatal Seizures. Epilepsia. 2023;64(10):2550-2570. doi:10.1111/epi.17745 [PubMed 37655702]
  70. Puente NW, Josephy PD. Analysis of the lidocaine metabolite 2,6-dimethylaniline in bovine and human milk. J Anal Toxicol. 2001;25(8):711-715. doi:10.1093/jat/25.8.711 [PubMed 11765029]
  71. Reece-Stremtan S, Campos M, Kokajko L; The Academy of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2017. Breastfeed Med. 2017;12(9):500-506. doi: 10.1089/bfm.2017.29054.srt. [PubMed 29624435]
  72. Refer to manufacturer’s labeling.
  73. Roman-Rodriguez CF, Toussaint T, Sherlock DJ, Fogel J, Hsu CD. Pre-emptive penile ring block with sucrose analgesia reduces pain response to neonatal circumcision. Urology. 2014;83(4):893-898. doi:10.1016/j.urology.2013.10.010 [PubMed 24275281]
  74. Rosenberg PH, Veering BT, Urmey WF. Maximum recommended doses of local anesthetics: a multifactorial concept. Reg Anesth Pain Med. 2004;29(6):564-575. doi:10.1016/j.rapm.2004.08.003 [PubMed 15635516]
  75. Rossi S, Buonocore G, Bellieni CV. Management of pain in newborn circumcision: a systematic review. Eur J Pediatr. 2021;180(1):13-20. doi:10.1007/s00431-020-03758-6 [PubMed 32748017]
  76. Samarin MJ, Mohrien KM, Oliphant CS. Continuous intravenous antiarrhythmic agents in the intensive care unit: strategies for safe and effective use of amiodarone, lidocaine, and procainamide. Crit Care Nurs Q. 2015;38(4):329-344. doi:10.1097/CNQ.0000000000000082 [PubMed 26335213]
  77. Schalk R, Schweigkofler U, Lotz G, Zacharowski K, Latasch L, Byhahn C. Efficacy of the EZ-IO needle driver for out-of-hospital intraosseous access--a preliminary, observational, multicenter study. Scand J Trauma Resusc Emerg Med. 2011;19:65. doi:10.1186/1757-7241-19-65. [PubMed 22029625]
  78. Sharara-Chami R, Lakissian Z, Charafeddine L, Milad N, El-Hout Y. Combination analgesia for neonatal circumcision: a randomized controlled trial. Pediatrics. 2017;140(6):e20171935. doi:10.1542/peds.2017-1935 [PubMed 29150457]
  79. Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. Pediatrics. 2020;145(1):e20193450. doi:10.1542/peds.2019-3450 [PubMed 31871244]
  80. Topjian AA, Raymond TT, Atkins D, et al. Part 4: Pediatric basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2020;142(16 Suppl 2):S469-S523. doi:10.1161/CIR.0000000000000901 [PubMed 33081526]
  81. Ulus A, Gürses E, Öztürk I, Serin S. Comparative evaluation of two different volumes of lidocaine in intravenous regional anesthesia. Med Sci Monit. 2013;19:978-983. doi:10.12659/MSM.889547 [PubMed 24220662]
  82. van den Broek MP, Huitema AD, van Hasselt JG, et al. Lidocaine (lignocaine) dosing regimen based upon a population pharmacokinetic model for preterm and term neonates with seizures. Clin Pharmacokinet. 2011;50(7):461-469. [PubMed 21651313]
  83. van den Broek MP, Rademaker CM, van Straaten HL, et al. Anticonvulsant treatment of asphyxiated newborns under hypothermia with lidocaine: efficacy, safety and dosing. Arch Dis Child Fetal Neonatal Ed. 2013;98(4):F341-345. [PubMed 23303304]
  84. Vanden Hoek TL, Morrison LJ, Shuster M, et al, “Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,” Circulation, 2010, 122(18 Suppl 3):829-61. [PubMed 20956228]
  85. Weeke LC, Toet MC, van Rooij LG, et al. Lidocaine response rate in a EEG-confirmed neonatal seizures: Retrospective study of 413 full-term and preterm infants. Epilepsia. 2016;57(2):233-242. [PubMed 26719344]
  86. World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. https://apps.who.int/iris/handle/10665/62435
  87. Xylocaine (lidocaine) [prescribing information]. Lake Zurich, IL: Fresenius Kabi USA; October 2024.
  88. Xylocaine injection for ventricular arrhythmias (lidocaine systemic) [prescribing information]. Schaumburg, IL: APP Pharmaceuticals LLC; May 2011.
  89. Xylocard (lidocaine solution, IV) [product monograph]. Oakville, Ontario, Canada: Aspen Pharmacare Canada Inc; December 2024.
  90. Zeisler JA, Gaarder TD, De Mesquita SA. Lidocaine excretion in breast milk. Drug Intell Clin Pharm. 1986;20(9):691-693. doi:10.1177/106002808602000913 [PubMed 3757781]
  91. Zipes DP and Jalife J, "Lidocaine," Cardiac Electrophysiology: From Cell to Bedside, 3rd ed, Philadelphia, PA: WB Saunders Co, 2000, 896.
Topic 10274 Version 613.0